Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

The study was carried out at 24 clinical sites across the UK and included 303 participants.

They say a rising tide lifts all boats, and that certainly seems to be the case with the new wave of drugs and devices for diabetes management. In a recent analysis (PDF), Abbott examined trends in ...

Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...

Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin.

Comments on this technology were invited from clinical experts working in the field and relevant patient organisations. The comments received are individual opinions and do not represent NICE's view.

Abbott Laboratories ABT recently presented late-breaking data on its FreeStyle Libre system at the American Diabetes Association’s (“ADA”) 81st Scientific Sessions. Data showed that this continuous ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...